45例噬血细胞综合征患儿的临床特点及预后分析

doi:10.12372/jcp.2025.25e0216

Abstract

Abstract:

Objective To analyze the clinical characteristics and prognostic factors of hemophagocytic syndrome (HPS) in children. Methods A retrospective analysis was conducted on the clinical data and follow-up information of 45 children with HPS admitted from January 2017 to July 2023. Results The median age of onset in the 45 children was 4.5 (2.1-10.0) years, all of whom started with fever. Infection-related HPS accounted for 77.8%, with Epstein-Barr virus (EBV) infection being the most common (85.7%). The overall survival rate of all children was (88.9±4.7)%. Univariate analysis showed that triglycerides≥3.8 mmol/L and lactate dehydrogenase≥2500 U/L were risk factors affecting the prognosis of children with HPS (P<0.05 for both), and multivariate analysis showed that triglycerides≥3.8 mmol/L was an independent risk factor affecting the prognosis of children with HPS (P=0.029). Conclusion HPS often starts with fever, and infection (especially EBV infection) is the most common cause; the levels of triglycerides and lactate dehydrogenase at initial diagnosis (especially triglycerides≥3.8 mmol/L) are key factors in assessing prognosis.

Key words: hemophagocytic syndrome, clinical characteristics, treatment, prognosis, child

CLC Number:

JIANG Wenxuan, YE Fanghua, XIAO Yixin, YANG Liangchun. Analysis of clinical characteristics and prognostic factors of 45 children with hemophagocytic syndrome[J].Journal of Clinical Pediatrics, 2025, 43(10): 762-767.

Figures/Tables 3

Figure 1

Table 1

Table 2

References 25

[1]	中国医师协会血液科医师分会, 中华医学会儿科学分会血液学组, 噬血细胞综合征中国专家联盟. 中国噬血细胞综合征诊断与治疗指南(2022年版)[J]. 中华医学杂志, 2022, 102(20): 1492-1499.
	Hematologists Branch of Chinese Medical Doctor Association, Hematology Group of Pediatrics Branch of Chinese Medical Association, Chinese Expert Alliance for Hemophagocytic Syndrome. Chinese Guidelines for the Diagnosis and Treatment of Hemophagocytic Syndrome (2022 Edition)[J]. Zhonghua Yixue Zazhi, 2022, 102(20): 1492-1499.
[2]	Lin M, Park S, Hayden A, et al. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review[J]. Ann Hematol, 2017, 96(8): 1241-1251. doi: 10.1007/s00277-017-2993-y pmid: 28497365
[3]	Henter J I, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2): 124-131.
[4]	Li X, Yan H P, Zhang X P, et al. Clinical profiles and risk factors of 7-day and 30-day mortality among 160 pediatric patients with hemophagocytic lymphohistiocytosis[J]. Orphanet J Rare Dis, 2020, 15(1): 229. doi: 10.1186/s13023-020-01515-4 pmid: 32867836
[5]	Morimoto A, Nakazawa Y, Ishii E. Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management[J]. Pediatr Int, 2016, 58(9): 817-825. doi: 10.1111/ped.13064 pmid: 27289085
[6]	Suzuki N, Morimoto A, Ohga S, et al. Characteristics of hemophagocytic lymphohistiocytosis in neonates: a nationwide survey in Japan[J]. J Pediatr, 2009, 155(2): 235-238.
[7]	Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan[J]. Int J Hematol, 2007, 86(1): 58-65. doi: 10.1532/IJH97.07012 pmid: 17675268
[8]	Aguayo F, Boccardo E, Corvalan A, et al. Interplay between Epstein-Barr virus infection and environmental xenobiotic exposure in cancer[J]. Infect Agent Cancer, 2021, 16(1): 50.
[9]	Noor A, Panwala A, Forouhar F, et al. Hepatitis caused by herpes viruses: A review[J]. J Dig Dis, 2018, 19(8): 446-455.
[10]	魏昂, 李志刚, 王天有. 噬血细胞综合征发病机制及治疗研究进展[J]. 中华实用儿科临床杂志, 2019, 34(3): 227-230.
	Wei A, Li ZG, Wang TY. Research progress on the Pathogenesis and Treatment of hemophagocytic syndrome[J]. Zhonghua Shiyong Erke Linchuang Zazhi, 2019, 34(3): 227-230.
[11]	Janka GE, Lehmberg K. Hemophagocytic lympho histiocytosis: pathogenesis and treatment[J]. Hematology Am Soc Hematol Educ Program, 2013: 605-611.
[12]	Chaturvedi V, Marsh RA, Zoref-Lorenz A, et al. T-cell activation profiles distinguish hemophagocytic lympho-histiocytosis and early sepsis[J]. Blood, 2021, 137(17): 2337-2346. doi: 10.1182/blood.2020009499 pmid: 33512385
[13]	Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma[J]. Mol Ther, 2014, 22(1): 132-139.
[14]	Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis[J]. J Clin Oncol, 2001, 19(10): 2665-2673. doi: 10.1200/JCO.2001.19.10.2665 pmid: 11352958
[15]	Trottestam H, Horne A, Arico M, et al. Chemoimmuno-therapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol[J]. Blood, 2011, 118(17): 4577-4584. doi: 10.1182/blood-2011-06-356261 pmid: 21900192
[16]	Zhang Q, Zhao Y Z, Ma H H, et al. A study of ruxolitinib response-based stratified treatment for pediatric hemo-phagocytic lymphohistiocytosis[J]. Blood, 2022, 139(24): 3493-3504.
[17]	Imashuku S, Tabata Y, Teramura T, et al. Treatment strategies for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH)[J]. Leuk Lymphoma, 2000, 39(1-2): 37-49.
[18]	Ishii E. Hemophagocytic lymphohistiocytosis in children: pathogenesis and treatment[J]. Front Pediatr, 2016, 4: 47. doi: 10.3389/fped.2016.00047 pmid: 27242976
[19]	Singh PP, Goyal A. Interleukin-6: a potent biomarker of mycobacterial infection[J]. Springerplus, 2013, 2: 686. doi: 10.1186/2193-1801-2-686 pmid: 24455461
[20]	Dufranc E, Del Bello A, Belliere J, et al. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome[J]. Crit Care, 2020, 24(1): 166.
[21]	程佩萱, 胡秀芬. 儿童特发性关节炎与巨噬细胞活化综合征[J]. 实用儿科临床杂志, 2009, 24(21): 1631-1633.
	Cheng PX, Hu XF. Idiopathic arthritis in children and macrophage activation syndrome[J]. Shiyong Erke Linchuang Zazhi, 2009, 24(21): 1631-1633.
[22]	Tang YM, Luo Z. Prognostic factors of early death in children with hemophagocytic lymphohistiocytosis[J]. Cytokine, 2018, 110: 481-482.
[23]	Wang X, Zhou Y, Sun Q, et al. Disparity analysis of clinical features and prognostic evaluation of hemophagocytic lymphohistiocytosis in pediatric and adult patients: a retrospective multicenter study of 525 cases in HHLWG[J]. Acta Haematol, 2023, 146(3): 185-195.
[24]	Okamoto M, Yamaguchi H, Isobe Y, et al. Analysis of triglyceride value in the diagnosis and treatment response of secondary hemophagocytic syndrome[J]. Intern Med, 2009, 48(10): 775-781.
[25]	赖冬波, 王嘉怡, 赵玉红, 等. 血清学指标对噬血细胞综合征患儿死亡预测价值的临床研究[J]. 中国小儿急救医学, 2013, 20(2): 144-148.
	Lai DB, Wang JY, Zhao YH, et al. Clinical study on the predictive value of serological indicators for death in children with hemophagocytic syndrome[J]. Zhongguo Xiaoer Jijiu Yixue, 2013, 20(2): 144-148.

临床特征	累积生存率/%	χ²值	P
年龄		0.02	0.896
≤3岁	88.2±7.8
>3岁	89.3±5.8
sCD25		0.33	0.564
增高	90.6±5.2
正常	84.6±10.0
NK细胞活性^1）		0.13	0.716
降低	90.5±6.4
正常	87.0±7.0
血红蛋白		0.25	0.617
≤100 g·L^－1	87.5±5.8
>100 g·L^－1	92.3±7.4
白细胞计数		3.72	0.054
≤2.0×10⁹·L^－1	77.8±9.8
>2.0×10⁹·L^－1	96.3±3.6
中性粒细胞计数		2.68	0.101
≤0.5×10⁹·L^－1	80.0±8.9
>0.5×10⁹·L^－1	96.0±3.9
血小板计数		0.07	0.797
≤30×10⁹·L^－1	85.7±13.2
>30×10·L^－1	89.5±5.0
血清铁蛋白		0.00	0.966
≥10 000 ng·mL^－1	88.9±7.4
<10 000 ng·mL^－1	88.9±6.0
三酰甘油		10.65	0.001
≥3.8 mmol·L^－1	63.6±14.5
<3.8 mmo·L^－1	97.1±2.9
纤维蛋白原		0.02	0.899
≤1.5 g·L^－1	88.5±6.3
>1.5 g·L^－1	89.5±7.0
乳酸脱氢酶		5.43	0.020
>2 500 U·L^－1	73.3±11.4
≤2 500 ·L^－1	96.7±3.3
丙氨酸氨基转移酶		0.38	0.540
升高	88.1±5.0
正常	100
天门冬氨酸氨基转移酶		0.97	0.324
升高	86.8±5.5
正常	100
总胆红素		0.21	0.648
升高	92.3±7.4
正常	87.5±5.8
直接胆红素		0.31	0.576
升高	92.9±6.9
正常	87.1±6.0
白蛋白		0.31	0.581
≤30 g·L^－1	84.6±10.0
>30 g·L^－1	90.6±5.2

影响因素	β	S.E.	Wald χ²	P	HR（95%CI）
白细胞计数≤2.0×10⁹·L^－1	0.844	1.198	0.496	0.481	2.325（0.222~24.322）
三酰甘油≥3.8 mmol·L^－1	2.592	1.191	4.739	0.029	13.360（1.295~137.862）
乳酸脱氢酶>2 500 U·L^－1	2.172	1.143	3.611	0.057	8.772（0.934~82.381）

Analysis of clinical characteristics and prognostic factors of 45 children with hemophagocytic syndrome

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 25

Related Articles 15

Metrics

Comments

Recommended 0

[1]	. Expert consensus on pre-symptomatic treatment for pediatric spinal muscular atrophy (2025 edition) [J]. Journal of Clinical Pediatrics, 2025, 43(9): 643-651.
[2]	LIU Yun, PAN Jingjing, SHEN Jinxin, ZOU Yunsu, CHENG Rui, FENG Yun, YANG Yang. Therapeutic efficacy of surfactant supplementation after pulmonary hemorrhage in improving clinical outcomes of preterm infants with gestational age <34 weeks [J]. Journal of Clinical Pediatrics, 2025, 43(9): 652-660.
[3]	ZHANG Wei, WANG Yang, DENG Wenhua, WU Yabin. Analysis of clinical manifestations, ciliary structure and genetic characteristics of primary ciliary dyskinesia in 14 children [J]. Journal of Clinical Pediatrics, 2025, 43(9): 680-685.
[4]	XIANG Linjuan, CHEN Xuexin, JIA Yanhui, WU Yuhang, CONG Xin, LI Wei, CHEN Yingying, CHEN Sun, HUANG Lisu. Prognostic factors analysis of adenovirus type 3 pneumonia in children [J]. Journal of Clinical Pediatrics, 2025, 43(9): 686-691.
[5]	WANG Jie, WU Bin, ZHANG Lannan, CHEN Kailan. Two cases of pediatric hepatosplenic T-cell lymphoma and literature review [J]. Journal of Clinical Pediatrics, 2025, 43(9): 698-704.
[6]	YE Zehui, JIANG Xiaoli. A case report of sirolimus in the treatment of diffuse pulmonary lymphangiomatosis in children [J]. Journal of Clinical Pediatrics, 2025, 43(9): 705-709.
[7]	DONG Suzhen, CHEN Hao, ZHANG Zhiyong, JIANG Fan. Applications of low field MRI in pediatrics and prenatal fetal diagnosis [J]. Journal of Clinical Pediatrics, 2025, 43(9): 710-715.
[8]	LI Zailing. Clinical characteristics, diagnosis and treatment progress of functional gastrointestinal disorders in infants aged 0-6 months [J]. Journal of Clinical Pediatrics, 2025, 43(8): 563-568.
[9]	SHI Xiaosong, FU Shijie, HE Xiaohua, LYU Hui, CHEN Houyang, CHEN Maolin, CHEN Jie. Antigenic genotypic characteristics and antibiotic resistance analysis of Bordetella pertussis in two regions of Fujian province [J]. Journal of Clinical Pediatrics, 2025, 43(8): 575-582.
[10]	PEI Pei, LI Weihua, HUAI Wan, YAO Ruen, GE Hejia, WANG Jiwen, WANG Xiumin, JI Wei, ZHOU Yunqing, HE Yingzhong, HAN Feng. Genetic and clinical characteristics analysis of 10 children with ATP1A2/ATP1A3 gene variants [J]. Journal of Clinical Pediatrics, 2025, 43(8): 590-597.
[11]	LI Heting, SUN Ruidi, JIANG Jun. Clinical features, prognosis and neurophysiological characteristics of children with acute anti-GQ1b antibody syndrome [J]. Journal of Clinical Pediatrics, 2025, 43(8): 604-609.
[12]	ZHANG Cheng, CAO Qiaoyu, ZHENG Luyao, LI Ming, GE Hongsong. Retrospective analysis of clinical features, dermoscopic characteristics and prognosis of acquired facial hyperpigmented macules in 54 pediatric cases [J]. Journal of Clinical Pediatrics, 2025, 43(8): 610-614.
[13]	Chinese Cooperative Group for the Management of Pediatric Enuresis Affiliated to Pediatric Nephrology Committee of Chinese Medical Doctor Association. Chinese expert consensus on management of nocturnal enuresis in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 483-499.
[14]	WANG Yingshuo, CHEN Zhimin. Leveraging digital intelligence to enhance the diagnosis, treatment, and management of pediatric bronchial asthma [J]. Journal of Clinical Pediatrics, 2025, 43(7): 500-504.
[15]	ZHAO Linchao, WANG Yingjie, JING Zhaohe, MAI Yumiao, SUN Pan, QIU Simin, NIU Hongyun, CHEN Zhiwei, DONG Pengpeng, LIU Jian. Analysis of the efficacy and prognosis of hematopoietic stem cell transplantation for inherited bone marrow failure syndrome in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 505-510.